Jeffrey T Guptill

List of Publications by Year
in descending order

43 papers	1,432 citations	471061 17 h-index	344852 36 g-index
44 all docs	44 docs citations	44 times ranked	1391 citing authors

#	Article	IF	Citations
1	Perioperative Outcomes of Thymectomy in Myasthenia Gravis: A Thoracic Surgery Database Analysis. Annals of Thoracic Surgery, 2022, 113, 904-910.	0.7	11
2	Identifying a patientâ€centered outcome measure for a comparative effectiveness treatment trial in myasthenia gravis. Muscle and Nerve, 2022, 65, 75-81.	1.0	4
3	Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurology, The, 2022, 21, 176-188.	4.9	74
4	Adverse Reactions in a Phase 1 Trial of the Anti-Malarial DM1157: An Example of Pharmacokinetic Modeling and Simulation Guiding Clinical Trial Decisions. Infectious Diseases and Therapy, 2022, 11, 841-852.	1.8	2
5	Classical Complement Pathway Inhibition in a â€œHumanâ€Onâ€Aâ€Chipâ€•Model of Autoimmune Demyelinating Neuropathies. Advanced Therapeutics, 2022, 5, .	1.6	17
6	The clinical need for clustered AChR cell-based assay testing of seronegative MG. Journal of Neuroimmunology, 2022, 367, 577850.	1.1	9
7	Randomized phase 2 study of <scp>ACE</scp>â€083, a <scp>muscleâ€promoting</scp> agent, in facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2022, 66, 50-62.	1.0	8
8	Knowledge and perceptions of the <scp>COVID</scp>â€19 pandemic among patients with myasthenia gravis. Muscle and Nerve, 2021, 63, 357-364.	1.0	13
9	The <scp>D</scp>uke myasthenia gravis clinic registry: <scp>I</scp>. <scp>D</scp>escription and demographics. Muscle and Nerve, 2021, 63, 209-216.	1.0	20
10	Reduced plasmablast frequency is associated with seronegative myasthenia gravis. Muscle and Nerve, 2021, 63, 577-585.	1.0	2
11	Normative dataset for plasma cytokines in healthy human adults. Data in Brief, 2021, 35, 106857.	0.5	11
12	Management/Treatment of Lambert-Eaton Myasthenic Syndrome. Current Treatment Options in Neurology, 2021, 23, 1.	0.7	0
13	Cellular changes in eculizumab early responders with generalized myasthenia gravis. Clinical Immunology, 2021, 231, 108830.	1.4	4
14	Inhibition of the transcription factor ROR-Î³ reduces pathogenic Th17 cells in acetylcholine receptor antibody positive myasthenia gravis. Experimental Neurology, 2020, 325, 113146.	2.0	10
15	COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurology, The, 2020, 19, 970-971.	4.9	85
16	Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis. Journal of Neuroimmunology, 2020, 345, 577279.	1.1	17
17	Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. Journal of the Neurological Sciences, 2020, 412, 116803.	0.3	110
18	Validation of the triple timed upâ€andâ€go test in Lambertâ€Eaton myasthenia. Muscle and Nerve, 2019, 60, 292-298.	1.0	5

#	Article	IF	Citations
19	Clinical outcome measures following plasma exchange for MG exacerbation. Annals of Clinical and Translational Neurology, 2019, 6, 2114-2119.	1.7	14
20	Establishment of normative ranges of the healthy human immune system with comprehensive polychromatic flow cytometry profiling. PLoS ONE, 2019, 14, e0225512.	1.1	20
21	Tacrolimus inhibits Th1 and Th17 responses in MuSK-antibody positive myasthenia gravis patients. Experimental Neurology, 2019, 312, 43-50.	2.0	23
22	Antagonism of the Neonatal Fc Receptor as an Emerging Treatment for Myasthenia Gravis. Frontiers in Immunology, 2019, 10, 3052.	2.2	54
23	Treatment Patterns and Costs of Chronic Inflammatory Demyelinating Polyneuropathy: A Claims Database Analysis. American Health and Drug Benefits, 2019, 12, 127-135.	0.5	2
24	Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers to Achieve Equal Systemic Drug Exposures. Journal of Pediatrics, 2018, 193, 102-108.e1.	0.9	24
25	Comparative effectiveness clinical trials to advance treatment of myasthenia gravis. Annals of the New York Academy of Sciences, 2018, 1413, 69-75.	1.8	2
26	Reliability of the tripleâ€timed upâ€andâ€go test. Muscle and Nerve, 2018, 57, 136-139.	1.0	11
27	B cells in the pathophysiology of myasthenia gravis. Muscle and Nerve, 2018, 57, 172-184.	1.0	87
28	Population Pharmacokinetics and Exploratory Exposureâ€Response Relationships of Diazepam in Children Treated for Status Epilepticus. CPT: Pharmacometrics and Systems Pharmacology, 2018, 7, 718-727.	1.3	4
29	Marked clinical and jitter improvement after eculizumab in refractory myasthenia. Muscle and Nerve, 2017, 56, E16-E18.	1.0	5
30	Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects. Journal of Clinical Pharmacology, 2017, 57, 770-776.	1.0	35
31	B10 Cell Frequencies and Suppressive Capacity in Myasthenia Gravis Are Associated with Disease Severity. Frontiers in Neurology, 2017, 8, 34.	1.1	23
32	Adaptive immune response to therapy in hmgcr autoantibody myopathy. Muscle and Nerve, 2016, 53, 313-317.	1.0	2
33	Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis. Autoimmunity, 2016, 49, 472-479.	1.2	71
34	Construction and validation of the chronic acquired polyneuropathy patientâ€reported index (CAPâ€PRI): A diseaseâ€specific, healthâ€related qualityâ€ofâ€life instrument. Muscle and Nerve, 2016, 54, 9-17.	1.0	17
35	Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis. Neurotherapeutics, 2016, 13, 118-131.	2.1	53
36	Assessment of the effects of lacosamide on sleep parameters in healthy subjects. Seizure: the Journal of the British Epilepsy Association, 2015, 25, 155-159.	0.9	13

#	Article	IF	Citations
37	Characterization of B cells in muscle-specific kinase antibody myasthenia gravis. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e77.	3.1	49
38	Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve, 2014, 50, 47-51.	1.0	23
39	Emerging Subspecialties in Neurology: Clinical development. Neurology, 2013, 80, e4-e7.	1.5	0
40	A Retrospective study of complications of therapeutic plasma exchange in myasthenia. Muscle and Nerve, 2013, 47, 170-176.	1.0	30
41	Antiâ€musk antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts. Muscle and Nerve, 2011, 44, 36-40.	1.0	289
42	Cost analysis of myasthenia gravis from a large U.S. insurance database. Muscle and Nerve, 2011, 44, 907-911.	1.0	33
43	Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Current Opinion in Neurology, 2010, 23, 530-535.	1.8	146